LA JOLLA, Calif., Jan. 23, 2018 -- via Network NewsWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, today announced that company CEO and President RJ Tesi, M.D., will present at NobleCon14, NOBLE Capital Markets’ 14th annual investor conference, at the W Hotel in Fort Lauderdale, Florida, on January 29 at 10:30 a.m. Eastern Standard Time.
A high-definition video webcast of the presentation will be available the following day on the Company's website, www.inmunebio.com, and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com and www.noblecapitalmarkets.com. A Microsoft Silverlight viewer is required (a free download from the presentation link) to participate. The webcast and presentation will be archived on the Company's website and on the Noble websites for 90 days following the event.
About INmune Bio: INmune Bio, Inc. is a private clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INkmune and INB03. INKmune is an NK cell therapeutic that primes the patient’s NK cells to attack their cancer. INB03 inhibits myeloid derived suppressor cells, which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors. To learn more, please visit www.inmunebio.com.
About Noble Capital Markets, Inc.: Noble Capital Markets, established in 1984, is an equity research-driven, full-service investment and merchant banking boutique focused on the healthcare, media & entertainment, technology, transportation & logistics and natural resources sectors. The company has offices in Boca Raton, New York, Boston and St. Louis. In addition to NobleCon, an annual multi-sector investor conference, and the Media, Finance & Investor Program, produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, Noble hosts numerous “non-deal” corporate road shows throughout the year across the United States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
[email protected]
www.inmunebio.com


Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Anta Sports Expands Global Footprint With Strategic Puma Stake
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



